Karolinska Development AB announces that the portfolio company Modus Therapeutics has received approval from the regulatory authorities in the Netherlands to carry out a clinical Phase 1b-study with sevuparin, a potential new treatment of sepsis/septic shock. Sevuparin is an innovative drug candidate based on a polysaccharide with the potential of limiting vascular injury and plasma leakage in patients suffering from sepsis/septic shock or other medical conditions involving systemic inflammation. The aim of the planned randomized, placebo-controlled Phase 1b-study is to investigate the effect of intravenously administrered sevuparin in dermal and systemic lipopolysaccharide-induced (LPS) inflammation in healthy individuals. The study will also evaluate sevuparin?s safety profile in combination with a standard of care prophylactic, anticoagulant heparin treatment. The study is designed using a well-established and recognized model that is utilized to mimic the early states of septic shock. Modus Therapeutics will conduct the study in collaboration with the Center for Human Drug Research (CHDR) in Leiden, the Netherlands, which is an experienced clinical research actor carrying an extensive expertise in inflammatory diseases and clinical studies. Karolinska Development's direct ownership interest, and indirect ownership interest via KDev Investment, in Modus Therapeutics amounts to 38% and 17%, respectively.